Haploidentical hematopoietic cell transplantation (haplo-HCT) is being increasingly used in acute leukemia patients as an alternative transplant modality when matched sibling or matched unrelated donors are unavailable. As several potential haploidentical relative donors are typically available for a given patient, optimizing donor selection to improve clinical outcome is crucial. The impact of donor age and kinship on the outcome of acute leukemia patients is not clearly established in this setting. Using the multinational registry of the acute leukemia working party of the European society for blood and marrow transplantation we retrospective analyzed the clinical outcome of 1270 acute myeloid leukemia and acute lymphoblastic leukemia patients who underwent haplo-HCT between 2005 and 2015. Patients over the age of 40 were significantly affected by increasing donor age resulting in higher non-relapse mortality (NRM) [Hazard ratio (HR)51.86, confidence interval (CI) 95%, 1.18-2.94; P 5 .007], inferior leukemia-free survival (LFS) (HR 5 1.59, CI 95%, 1.13-2.24; P 5 .007), and overall survival (OS) (HR 5 1.74, CI 95%, 1.22-2.47; P 5 .002) when donors were over the age of 40. Additionally, kinship was found to be prognostically significant as patients transplanted from children donors over the age of 35 experienced an increased rate of NRM (HR 5 1.82, CI 95%, 1.13-2.9; P 5 .01), inferior LFS (HR 5 1.5, CI 95%, 1.05-2.13; P 5 .03), and OS (HR 5 1.5, CI 95%, 1.04-2.15; P 5 .03). For patients younger than 40 years, donor age and kinship were mostly not clinically impactful. Our data establish donor age and kinship as significant determinants of outcome following haplo-HCT for acute leukemia patients.
| M E TH ODS

| Study design and data collection
The current analysis was a retrospective multicenter analysis per- 
| Statistical analysis
The main endpoints of the study were non-relapse mortality (NRM), defined as death without previous relapse; relapse incidence (RI), defined on the basis of morphological evidence of leukemia in bone marrow or other extramedullary organs; leukemia-free survival (LFS), defined as the time from transplantation to first event (either relapse or death in complete remission); refined GVHD-free/relapse-free survival (GRFS), defined as survival without the following events: grade 3-4 acute GVHD, severe cGVHD, disease relapse, or death from any cause after Haplo-SCT
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; and overall survival. Cumulative incidence curves were used for RI and NRM in a competing risks setting, since death and relapse are competing. Probabilities of OS, LFS, and GRFS were calculated using the Kaplan-Meier estimate. The probabilities of NRM, RI, acute and chronic GVHD were calculated using the cumulative incidence estimator to accommodate for competing risks. 14 Univariate analyses were done using the Gray's test for cumulative incidence functions and the log rank test for OS, GRFS, and LFS. A Cox proportional hazards model was used for multivariate regression. Variables included in multivariate models were either significantly or unbalanced between the donor age groups, or known to have an impact on outcome studied. Results were expressed as the hazard ratio (HR) with the 95% confidence interval (95% CI). Proportional hazards assumptions were checked systematically for all proposed models using the Grambsch-Therneau residual-based test.
Initially we included both donor age and kinship as continuous variables in the Cox regression model. As the assumption of log-linearity (linearity between HR in each quintiles of donor age and outcome) was not verified, we categorized donor age using a cutoff of 40 years as planned in the protocol. Since donor age was related to kinship in the two cohorts of patients (over or under the age of 40), we also investigated the association between donor age and outcome in 4 groups of patients: 1. patients less than 40 years of age transplanted from a parent; 2. patients under the age of 40 transplanted from a sibling; 3.
patients over 40 years of age transplanted from a child; 4. patients more than 40 years of age transplanted from a sibling. In each group, we then determined the optimal threshold of donor age (i.e. best predictor of clinical outcome) using methodology previously described by Hothorn and Zeileis. 15 All tests were two-sided with the type I error rate fixed at 0.05.
Statistical analyses were performed with SPSS 22.0 (SPSS Inc, Chicago, Table S1 ).
3.3 | Impact of donor age on patient outcome in patients over the age of 40
To determine the differential impact of donor age on patient outcome, we proceeded with a separate analysis for patients over and under the age of 40. As shown in Supporting Information Table S2 which summarizes the baseline characteristics of patients over the age of 40, patients with younger donors tended to be older (57 vs. 53; P 5 .032) whereas donors younger than 40 years of age were for the most part children of the patients (91% vs. 19%; P < .001) as opposed to older donors who were mostly siblings (80% vs. 8%; P < .001). Next, a univariate analysis comparing the clinical outcomes of patients in this age group was carried out to determine whether outcome differed among patients with donors over and under the age of 40, and according to donor kinship, namely sibling donor versus child donor. As shown in Supplementary Table S3 , patients with younger donors experienced improved LFS and OS rates compared to their counterparts with older donors (41% vs. 32%; P 5 .03, and 45% vs. 35%; P 5 .01, respectively).
In this age group of patients over 40, kinship did not impact on patient outcome in a statistically significant manner, thus patients had comparable outcomes whether they were transplanted from their sibling or child.
We then carried out a multivariate analysis ( 
| Focused assessment of optimal donor subsets for patients over the age of 40
To better characterize the specific patient subsets which would benefit from specific donor pools, we made use of methodology previously described by Hothorn and Zeileis, 15 allowing us to determine that the optimal discriminating age cutoff for prognostication was 35 years and 41 years for children donors and sibling donors, respectively. As shown in Supplementary Figure S1 and Table S4 , patients transplanted from their children had inferior NRM, LFS, OS, and GRFS rates when the donors' age was over 35. In the multivariate analysis presented in Table   3 , transplantation from children donors over the age of 35 was associated with an increased risk of NRM (HR 5 1.82, CI 95%, 1.13-2.9; 
| Focused assessment of optimal donor subsets for patients younger than 40
In line with the subgroup analysis performed above, we wanted to determine specifically in younger patients whether donor age affected prognosis with respect to kinship. In this patient age group it was determined that for parent donors, the optimal cutoff age was 51, and as summarized in Supporting Information Table S9 , a multivariate analysis indicated that when donor age was more than 51 years of age, 
| D I SCUSSION
As haplo-HCT is transitioning into the mainstream of the stem cell transplantation field, choosing the best available donor is becoming a major priority. Our data suggest age 40 as a prognostically meaningful threshold with significant practical implications for patients, wherein patients over the age of 40 may benefit from a younger donor especially when the donor is their child. Conversely, we show that for patients under the age of 40, donor age for the most part is not as clinically significant.
Recently published donor selection algorithms for haplo-HCT [16] [17] [18] have designated a myriad of clinical, 11, 12 serological, 9, 10, 19 and immunological 20 parameters constituting the backbone for optimal donor selection in this setting. Whereas most of these have not been rigorously validated for haplo-HCT, a particular emphasis has been placed on donor age as this parameter is readily available and potentially modifiable when considering a specific donor from a potential donor pool consisting of several siblings and children. The theme of donor age has been extensively investigated in hematopoietic cell transplantation in the past three decades with data generally confirming that patients receiving grafts from younger donors experience superior survival [21] [22] [23] [24] [25] concomitant to a decreased incidence of acute and chronic GVHD. 26, 27 Our analysis shows that in patients over the age of 40, having an older donor, namely over the age of 40, is tightly associated with increased NRM and inferior LFS translating into inferior OS. Moreover, in this age group we established kinship to be a major determinant of patient outcome as increasing donor age did not affect outcome when patients were transplanted from their siblings whereas those patients receiving grafts from their children did experience worse outcome when their donor was over the age of 35. Our findings are generally in line with those of Wang and colleagues 12 with several noteworthy exceptions. In contrast to their results we did not find male gender to be significantly associated with superior clinical outcome, nor did we observe children donors to be superior to sibling donors in terms of GVHD. These differences may be accounted for by considering several factors: our analysis was restricted to a uniform cohort of acute leukemia patients whereas theirs consisted of a mixed cohort which comprised a substantial segment of patients with diseases other than acute leukemia. Additionally, post-transplantation cyclophosphamide was widely used for patients in our analysis while the Chinese analysis uniformly used ATG for T-cell depletion.
Interestingly, we found that for younger patients, donor age and kinship were not as clinically impactful. The only clear association in this age group pertained to a decreased rate of extensive chronic GVHD when donors were over the age of 55, an observation which diverges from previously published data in matched unrelated donors. 21, 26 The reasons for this observation are not completely clear but we note that as part of the aging process there is an increase in the number of peripheral blood CD4 We believe that the implications of our findings are of importance for future donor selection algorithms in haplo-HCT and will guide clinicians in making a rationale determination of the optimal donor for a specific patient. Furthermore, our findings underscore the unique immunological milieu of haplo-HCT where considerations need to be made regarding donor-recipient rapports between patients, their children, siblings, and parents.
As with any multicenter registry analysis, our results should be interpreted cautiously owing to inherent biases in data collection and variations in clinical practice among participating institutions. Additionally, we note that the group of patients over the age of 40 who were transplanted from younger donors (under the age of 41) consisted of only 47 patients and thus the lack of statistical significance (P 5 .06) with regard to OS and LFS may have resulted from the lack of sufficient statistical power.
In aggregate, the key findings of this analysis uncover an additional facet of the complexities involved in providing the best outcome for acute leukemia patients undergoing haplo-HCT, and will hopefully further inform the maturing field of haploidentical transplantation.
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